Interventions that impact the timing of recovery following acute injury may improve future outcomes for patients.

A study of 280,000 U.S. veterans, including 56,000 African Americans, has identified in greater detail than ever before the genetic architecture of kidney function and chronic kidney disease (CKD), according to researchers at Vanderbilt University Medical Center and their colleagues.

A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases.

Men are more susceptible to progressive kidney disease than women; new VUMC studies point to differences in the expression and activation of the EGF receptor.

The American Society of Gene and Cell Therapy (ASGCT) has appointed Matthew Wilson, MD, PhD, associate professor of Medicine in Vanderbilt’s Division of Nephrology and Hypertension, to its board of directors. Beginning in May 2019, Wilson will serve a three-year term as an at-large director.

Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI).

Using gene transfer technologies to reprogram adult human kidney cells could lead to novel therapies for chronic kidney disease.